bannerbanner

Useful links

Please download or view the following resources to
learn more about insomnia, its treatment options,
and DAYVIGO™ (lemborexant)

Expert opinion on DAYVIGO™ - Coming Soon

DAYVIGO™ Patient Brochure

Canadian Sleep & Circadian Network (CSCN)

Insomnia Academy

INDICATION AND CLINICAL USE:

Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder. Consequently, a
decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully
evaluated.

DAYVIGO™ (lemborexant) is indicated for the treatment of insomnia, characterized by difficulties with sleep
onset and/or sleep maintenance.

DAYVIGO™ is not recommended for patients under the age of 18 years.

DAYVIGO™ is not recommended in patients with severe hepatic impairment.

CONTRAINDICATIONS:

Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or
component of the container.

Patients with narcolepsy. 

RELEVANT WARNINGS AND PRECAUTIONS:

Abnormal thinking and behavioural changes 

CNS depressant effects (including alcohol) and daytime impairment 

Complex sleep behaviours 

Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms 

Worsening of depression/suicidal ideation 

Co-morbid diagnoses 

Drug interactions – inhibitors and inducers of CYP3A 

Driving and operating machinery 

Patients with dependence/tolerance and abuse liability 

Patients with hepatic, biliary, or pancreatic impairment 

Patients with compromised respiratory function 

Pregnant or breastfeeding women 

FOR MORE INFORMATION

Please see the Product Monograph for important information on adverse reactions, drug interactions, and dosing
not discussed in this piece.


Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder.
Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the
patient has been carefully evaluated.

DAYVIGO™ is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or
sleep maintenance.

Click here for additional safety information and for a link to the product monograph, discussing
contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical
use.